Xavier Masramon
Overview
Explore the profile of Xavier Masramon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
249
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Winchester S, Castellarnau A, Jabbar K, Nadir M, Ranasinghe K, Masramon X, et al.
Pharmaceutics
. 2024 Sep;
16(9).
PMID: 39339209
Background/objectives: Dendrimer-based astodrimer sodium nasal spray was assessed for its ability to reduce SARS-CoV-2 load in outpatients with COVID-19, which remains a severe illness for vulnerable groups. Methods: This was...
2.
Hebert A, Rosen T, Albareda Lopez N, Zsolt I, Masramon X
Int J Womens Dermatol
. 2020 Apr;
6(2):109-115.
PMID: 32258344
Background: Ozenoxacin is a topical antibiotic approved in the United States for treatment of impetigo in adults and children age ≥2 months. This analysis evaluated the efficacy and safety of...
3.
Torrelo A, Grimalt R, Masramon X, Albareda Lopez N, Zsolt I
Dermatology
. 2020 Jan;
236(3):199-207.
PMID: 31958794
Background: Ozenoxacin is a topical antibiotic approved in Europe to treat non-bullous impetigo in adults and children aged ≥6 months. This analysis evaluated the efficacy and safety of ozenoxacin in...
4.
Hebert A, Albareda N, Rosen T, Torrelo A, Grimalt R, Rosenberg N, et al.
J Drugs Dermatol
. 2018 Oct;
17(10):1051-1057.
PMID: 30365584
Ozenoxacin is a novel topical antibacterial agent with potent bactericidal activity against Gram-positive bacteria that has been developed as a 1% cream for treatment of impetigo. This article presents pooled...
5.
Gramunt N, Sanchez-Benavides G, Buschke H, Dieguez-Vide F, Pena-Casanova J, Masramon X, et al.
J Alzheimers Dis
. 2016 Apr;
52(1):283-93.
PMID: 27060959
Background: The Memory Binding Test (MBT) is emerging as a promising tool for the detection of subtle memory impairment suggestive of Alzheimer's disease (AD). For such a test to be...
6.
Gramunt N, Sanchez-Benavides G, Buschke H, Lipton R, Masramon X, Gispert J, et al.
J Alzheimers Dis
. 2016 Feb;
50(4):999-1010.
PMID: 26836167
Background: Episodic memory testing is fundamental for the diagnosis of Alzheimer's disease (AD). Although the Free and Cued Selective Reminding Test (FCSRT) is widely used for this purpose, it may...
7.
Gramunt N, Buschke H, Sanchez-Benavides G, Lipton R, Pena-Casanova J, Dieguez-Vide F, et al.
J Alzheimers Dis
. 2015 Sep;
48(3):613-25.
PMID: 26402091
Background: The Memory Binding Test (MBT) is a novel test based on the learning of two lists of words, developed to detect early memory impairment suggestive of Alzheimer's disease (AD)....
8.
Perez C, Navarro A, Saldana M, Masramon X, Perez M, Rejas J
Pain Med
. 2013 Dec;
14(12):1954-63.
PMID: 24330229
Context And Objective: To describe clinical and resource utilization patterns in patients with refractory neuropathic pain (NeP) who were prescribed pregabalin for the first time in routine medical practice in...
9.
Saldana M, Perez C, Navarro A, Masramon X, Rejas J
Clin Drug Investig
. 2012 Apr;
32(6):401-12.
PMID: 22480279
Background: It has been suggested that peripheral neuropathic pain (PNP) may affect up to 3% of the general population. PNP has a substantial negative impact on patient functioning and quality...
10.
Navarro A, Saldana M, Perez C, Masramon X, Rejas J
Pain Pract
. 2011 Oct;
12(5):382-93.
PMID: 22004531
Purpose: To analyze the changes in pain severity and associated costs resulting from resource utilization and reduced productivity in patients with gabapentin-refractory peripheral neuropathic pain who switched to pregabalin therapy...